Anti-TNF-α treatment modulates SASP and SASP-related microRNAs in endothelial cells and in circulating angiogenic cells

Francesco Prattichizzo, Angelica Giuliani, Rina Recchioni, Massimiliano Bonafè, Fiorella Marcheselli, Sabrina De Carolis, Anna Campanati, Katia Giuliodori, Maria Rita Rippo, Francesca Brugè, Luca Tiano, Carla Micucci, Antonio Ceriello, Annamaria Offidani, Antonio Domenico Procopio, Fabiola Olivieri

Research output: Contribution to journalArticle

32 Citations (Scopus)

Abstract

Endothelial cell senescence is characterized by acquisition of senescence-associated secretory phenotype (SASP), able to promote inflammaging and cancer progression. Emerging evidence suggest that preventing SASP development could help to slow the rate of aging and the progression of age-related diseases, including cancer. Aim of this study was to evaluate whether and how adalimumab, a monoclonal antibody directed against tumor necrosis factor-α (TNF-α), a major SASP component, can prevent the SASP. A three-pronged approach has been adopted to assess the if adalimumab is able to: i) modulate a panel of classic and novel senescence- and SASP-associated markers (interleukin [IL]-6, senescence associated-β-galactosidase, p16/Ink4a, plasminogen activator inhibitor 1, endothelial nitric oxide synthase, miR-146a-5p/Irak1 and miR-126-3p/Spred1) in human umbilical vein endothelial cells (HUVECs); ii) reduce the paracrine effects of senescent HUVECs' secretome on MCF-7 breast cancer cells, through wound healing and mammosphere assay; and iii) exert significant decrease of miR-146a-5p and increase of miR-126-3p in circulating angiogenic cells (CACs) from psoriasis patients receiving adalimumab in monotherapy. TNF-α blockade associated with adalimumab induced significant reduction in released IL-6 and significant increase in eNOS and miR-126-3p expression levels in long-term HUVEC cultures. A significant reduction in miR-146a-5p expression levels both in long-term HUVEC cultures and in CACs isolated from psoriasis patients was also evident. Interestingly, conditioned medium from senescent HUVECs treated with adalimumab was less consistent than medium from untreated cells in inducing migration- and mammosphere- promoting effects on MCF-7 cells. Our findings suggest that adalimumab can induce epigenetic modifications in cells undergoing senescence, thus contributing to the attenuation of SASP tumor-promoting effects.

Original languageEnglish
Pages (from-to)11945-11958
Number of pages14
JournalOncotarget
Volume7
Issue number11
DOIs
Publication statusPublished - Mar 15 2016

Fingerprint

MicroRNAs
Endothelial Cells
Tumor Necrosis Factor-alpha
Human Umbilical Vein Endothelial Cells
Phenotype
Cell Aging
Therapeutics
Psoriasis
Interleukin-6
Cell Culture Techniques
Galactosidases
Secretory Component
Neoplasms
Nitric Oxide Synthase Type III
Plasminogen Activator Inhibitor 1
MCF-7 Cells
Conditioned Culture Medium
Epigenomics
Wound Healing
Adalimumab

Keywords

  • Gerotarget
  • HUVEC
  • miR-126-3p
  • miR-146α-5p
  • Replicative senescence
  • SASP

ASJC Scopus subject areas

  • Oncology

Cite this

Anti-TNF-α treatment modulates SASP and SASP-related microRNAs in endothelial cells and in circulating angiogenic cells. / Prattichizzo, Francesco; Giuliani, Angelica; Recchioni, Rina; Bonafè, Massimiliano; Marcheselli, Fiorella; De Carolis, Sabrina; Campanati, Anna; Giuliodori, Katia; Rippo, Maria Rita; Brugè, Francesca; Tiano, Luca; Micucci, Carla; Ceriello, Antonio; Offidani, Annamaria; Procopio, Antonio Domenico; Olivieri, Fabiola.

In: Oncotarget, Vol. 7, No. 11, 15.03.2016, p. 11945-11958.

Research output: Contribution to journalArticle

Prattichizzo, F, Giuliani, A, Recchioni, R, Bonafè, M, Marcheselli, F, De Carolis, S, Campanati, A, Giuliodori, K, Rippo, MR, Brugè, F, Tiano, L, Micucci, C, Ceriello, A, Offidani, A, Procopio, AD & Olivieri, F 2016, 'Anti-TNF-α treatment modulates SASP and SASP-related microRNAs in endothelial cells and in circulating angiogenic cells', Oncotarget, vol. 7, no. 11, pp. 11945-11958. https://doi.org/10.18632/oncotarget.7858
Prattichizzo, Francesco ; Giuliani, Angelica ; Recchioni, Rina ; Bonafè, Massimiliano ; Marcheselli, Fiorella ; De Carolis, Sabrina ; Campanati, Anna ; Giuliodori, Katia ; Rippo, Maria Rita ; Brugè, Francesca ; Tiano, Luca ; Micucci, Carla ; Ceriello, Antonio ; Offidani, Annamaria ; Procopio, Antonio Domenico ; Olivieri, Fabiola. / Anti-TNF-α treatment modulates SASP and SASP-related microRNAs in endothelial cells and in circulating angiogenic cells. In: Oncotarget. 2016 ; Vol. 7, No. 11. pp. 11945-11958.
@article{d24409459d6a4c0b80f6ea24e863e8a8,
title = "Anti-TNF-α treatment modulates SASP and SASP-related microRNAs in endothelial cells and in circulating angiogenic cells",
abstract = "Endothelial cell senescence is characterized by acquisition of senescence-associated secretory phenotype (SASP), able to promote inflammaging and cancer progression. Emerging evidence suggest that preventing SASP development could help to slow the rate of aging and the progression of age-related diseases, including cancer. Aim of this study was to evaluate whether and how adalimumab, a monoclonal antibody directed against tumor necrosis factor-α (TNF-α), a major SASP component, can prevent the SASP. A three-pronged approach has been adopted to assess the if adalimumab is able to: i) modulate a panel of classic and novel senescence- and SASP-associated markers (interleukin [IL]-6, senescence associated-β-galactosidase, p16/Ink4a, plasminogen activator inhibitor 1, endothelial nitric oxide synthase, miR-146a-5p/Irak1 and miR-126-3p/Spred1) in human umbilical vein endothelial cells (HUVECs); ii) reduce the paracrine effects of senescent HUVECs' secretome on MCF-7 breast cancer cells, through wound healing and mammosphere assay; and iii) exert significant decrease of miR-146a-5p and increase of miR-126-3p in circulating angiogenic cells (CACs) from psoriasis patients receiving adalimumab in monotherapy. TNF-α blockade associated with adalimumab induced significant reduction in released IL-6 and significant increase in eNOS and miR-126-3p expression levels in long-term HUVEC cultures. A significant reduction in miR-146a-5p expression levels both in long-term HUVEC cultures and in CACs isolated from psoriasis patients was also evident. Interestingly, conditioned medium from senescent HUVECs treated with adalimumab was less consistent than medium from untreated cells in inducing migration- and mammosphere- promoting effects on MCF-7 cells. Our findings suggest that adalimumab can induce epigenetic modifications in cells undergoing senescence, thus contributing to the attenuation of SASP tumor-promoting effects.",
keywords = "Gerotarget, HUVEC, miR-126-3p, miR-146α-5p, Replicative senescence, SASP",
author = "Francesco Prattichizzo and Angelica Giuliani and Rina Recchioni and Massimiliano Bonaf{\`e} and Fiorella Marcheselli and {De Carolis}, Sabrina and Anna Campanati and Katia Giuliodori and Rippo, {Maria Rita} and Francesca Brug{\`e} and Luca Tiano and Carla Micucci and Antonio Ceriello and Annamaria Offidani and Procopio, {Antonio Domenico} and Fabiola Olivieri",
year = "2016",
month = "3",
day = "15",
doi = "10.18632/oncotarget.7858",
language = "English",
volume = "7",
pages = "11945--11958",
journal = "Oncotarget",
issn = "1949-2553",
publisher = "Impact Journals LLC",
number = "11",

}

TY - JOUR

T1 - Anti-TNF-α treatment modulates SASP and SASP-related microRNAs in endothelial cells and in circulating angiogenic cells

AU - Prattichizzo, Francesco

AU - Giuliani, Angelica

AU - Recchioni, Rina

AU - Bonafè, Massimiliano

AU - Marcheselli, Fiorella

AU - De Carolis, Sabrina

AU - Campanati, Anna

AU - Giuliodori, Katia

AU - Rippo, Maria Rita

AU - Brugè, Francesca

AU - Tiano, Luca

AU - Micucci, Carla

AU - Ceriello, Antonio

AU - Offidani, Annamaria

AU - Procopio, Antonio Domenico

AU - Olivieri, Fabiola

PY - 2016/3/15

Y1 - 2016/3/15

N2 - Endothelial cell senescence is characterized by acquisition of senescence-associated secretory phenotype (SASP), able to promote inflammaging and cancer progression. Emerging evidence suggest that preventing SASP development could help to slow the rate of aging and the progression of age-related diseases, including cancer. Aim of this study was to evaluate whether and how adalimumab, a monoclonal antibody directed against tumor necrosis factor-α (TNF-α), a major SASP component, can prevent the SASP. A three-pronged approach has been adopted to assess the if adalimumab is able to: i) modulate a panel of classic and novel senescence- and SASP-associated markers (interleukin [IL]-6, senescence associated-β-galactosidase, p16/Ink4a, plasminogen activator inhibitor 1, endothelial nitric oxide synthase, miR-146a-5p/Irak1 and miR-126-3p/Spred1) in human umbilical vein endothelial cells (HUVECs); ii) reduce the paracrine effects of senescent HUVECs' secretome on MCF-7 breast cancer cells, through wound healing and mammosphere assay; and iii) exert significant decrease of miR-146a-5p and increase of miR-126-3p in circulating angiogenic cells (CACs) from psoriasis patients receiving adalimumab in monotherapy. TNF-α blockade associated with adalimumab induced significant reduction in released IL-6 and significant increase in eNOS and miR-126-3p expression levels in long-term HUVEC cultures. A significant reduction in miR-146a-5p expression levels both in long-term HUVEC cultures and in CACs isolated from psoriasis patients was also evident. Interestingly, conditioned medium from senescent HUVECs treated with adalimumab was less consistent than medium from untreated cells in inducing migration- and mammosphere- promoting effects on MCF-7 cells. Our findings suggest that adalimumab can induce epigenetic modifications in cells undergoing senescence, thus contributing to the attenuation of SASP tumor-promoting effects.

AB - Endothelial cell senescence is characterized by acquisition of senescence-associated secretory phenotype (SASP), able to promote inflammaging and cancer progression. Emerging evidence suggest that preventing SASP development could help to slow the rate of aging and the progression of age-related diseases, including cancer. Aim of this study was to evaluate whether and how adalimumab, a monoclonal antibody directed against tumor necrosis factor-α (TNF-α), a major SASP component, can prevent the SASP. A three-pronged approach has been adopted to assess the if adalimumab is able to: i) modulate a panel of classic and novel senescence- and SASP-associated markers (interleukin [IL]-6, senescence associated-β-galactosidase, p16/Ink4a, plasminogen activator inhibitor 1, endothelial nitric oxide synthase, miR-146a-5p/Irak1 and miR-126-3p/Spred1) in human umbilical vein endothelial cells (HUVECs); ii) reduce the paracrine effects of senescent HUVECs' secretome on MCF-7 breast cancer cells, through wound healing and mammosphere assay; and iii) exert significant decrease of miR-146a-5p and increase of miR-126-3p in circulating angiogenic cells (CACs) from psoriasis patients receiving adalimumab in monotherapy. TNF-α blockade associated with adalimumab induced significant reduction in released IL-6 and significant increase in eNOS and miR-126-3p expression levels in long-term HUVEC cultures. A significant reduction in miR-146a-5p expression levels both in long-term HUVEC cultures and in CACs isolated from psoriasis patients was also evident. Interestingly, conditioned medium from senescent HUVECs treated with adalimumab was less consistent than medium from untreated cells in inducing migration- and mammosphere- promoting effects on MCF-7 cells. Our findings suggest that adalimumab can induce epigenetic modifications in cells undergoing senescence, thus contributing to the attenuation of SASP tumor-promoting effects.

KW - Gerotarget

KW - HUVEC

KW - miR-126-3p

KW - miR-146α-5p

KW - Replicative senescence

KW - SASP

UR - http://www.scopus.com/inward/record.url?scp=84962808708&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84962808708&partnerID=8YFLogxK

U2 - 10.18632/oncotarget.7858

DO - 10.18632/oncotarget.7858

M3 - Article

AN - SCOPUS:84962808708

VL - 7

SP - 11945

EP - 11958

JO - Oncotarget

JF - Oncotarget

SN - 1949-2553

IS - 11

ER -